| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Position Statement |
New Mexico Clinical Research & Osteoporosis Center (E.M.L.), Albuquerque, New Mexico 87106; University of Cincinnati College of Medicine (N.B.W.), Cincinnati, Ohio 45267; Oregon Osteoporosis Center (M.R.M.), Portland, Oregon 97213; Texas Institute for Reproductive Medicine and Endocrinology (S.M.P.), Houston, Texas 77054; Stanford University School of Medicine (L.K.B.), Stanford, California 94305; University of California at San Francisco (J.A.S.), San Francisco, California 94143; and Virginia Commonwealth University (R.W.D.), Richmond, Virginia 23298
Address all correspondence and requests for reprints to: E. Michael Lewiecki, M.D., New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street Northeast, Albuquerque, New Mexico 87106. E-mail: lewiecki{at}aol.com.
The International Society for Clinical Densitometry (ISCD) periodically holds Position Development Conferences for the purpose of establishing standards and guidelines for indications, acquisition, and interpretation of bone density tests. Topics are selected for consideration by the ISCD Scientific Advisory Committee, reviewed by scientific working groups, and presented to an international panel of experts. Topic categories addressed to date include indications for bone density testing, selection of reference databases for T-scores and Z-scores, clinical applications for central and peripheral bone densitometry, serial bone density testing, instrument precision assessment, phantom scanning and calibration testing, requirements for a bone density report, nomenclature, and diagnosis of osteoporosis in postmenopausal women, premenopausal women, men, and children. After an open session for public comment and discussion, the panel convenes for consideration of each topic and makes recommendations for positions to the ISCD Board of Directors. Recommendations that are accepted become the Official Positions of the ISCD. This Special Report summarizes the methodology of the ISCD Position Development Conferences and presents selected Official Positions of general interest.
This work was supported by The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and Aventis Pharmaceuticals); Eli Lilly & Co.; GE Medical Systems LUNAR; Hologic, Inc.; and Merck Human Health.
The complete ISCD position papers were previously published in J Clin Densitom 7:163 (2004).
Abbreviations: BMD, Bone mineral density; DXA, dual-energy x-ray absorptiometry; ISCD, International Society for Clinical Densitometry; PA, posterior-anterior; PDC, Position Development Conference; SAC, Scientific Advisory Committee; WHO, World Health Organization.
This article has been cited by other articles:
![]() |
E. J. MacLaughlin and C. L. Raehl ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults Am. J. Health Syst. Pharm., February 15, 2008; 65(4): 343 - 357. [Full Text] [PDF] |
||||
![]() |
S. L. Greenspan Approach to the Prostate Cancer Patient with Bone Disease J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 2 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. G. Bone, D. P. Kiel, R. S. Lindsay, E. M. Lewiecki, M. A. Bolognese, E. T. Leary, W. Lowe, and M. R. McClung Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4671 - 4677. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gilsanz and T. Wren Assessment of Bone Acquisition in Childhood and Adolescence Pediatrics, March 1, 2007; 119(Supplement_2): S145 - S149. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |